Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jan
18
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
HCC LLM Advice and Treatment Concordance
Can a Genetic Variant Affect the Efficacy of Abiraterone
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo